Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Executive ChangeItem 5.02 · 8-KHIGH RiskNegative

Retinalgenix Technologies Inc.

retinalgenix.com
Filed: Mar 22, 2026Apollo Beach, FloridaCIK: 0001836295Biotechnology
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Michael Cory Zwerling resigned as CFO of Retinalgenix Technologies Inc. effective immediately on March 22, 2026, creating a leadership gap in financial management that could impact the company's financial strategy and operational continuity.

Key Takeaways

CFO departure effective immediately with no replacement identified, creating potential gaps in financial oversight and reporting

Resignation may signal underlying issues with financial direction, strategy, or company operations that warrant investor scrutiny

1 more takeaway

Filing Overview

Form Type8-K
Filing DateMar 22, 2026
Item5.02
CategoryExecutive Change
CIK0001836295
Accession #333-258528
Risk LevelHIGH
SentimentNegative
Signalrisk
Topics
executive departureleadership transition

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings